SWKS
36
3
MTB
56
-3
XRAY
22
2
BMY
43
-3
AN
43
2
PRU
51
-3
MCK
59
13
LB
38
-3
KR
40
3
KIM
66
2
AMAT
43
2
FDX
39
-5
CRM
59
2
NI
58
-5
PBI
32
-3
FITB
52
-4
CFG
54
-4
LH
40
-2
FLS
67
4
MO
57
-3
SWKS
36
3
MTB
56
-3
XRAY
22
2
BMY
43
-3
AN
43
2
PRU
51
-3
MCK
59
13
LB
38
-3
KR
40
3
KIM
66
2
AMAT
43
2
FDX
39
-5
CRM
59
2
NI
58
-5
PBI
32
-3
FITB
52
-4
CFG
54
-4
LH
40
-2
FLS
67
4
MO
57
-3
Financhill
Back

MoonLake Immunotherapeutics Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Sell
39

MLTX
MoonLake Immunotherapeutics

Last Price:
46.48
Seasonality Move:
18.28%

7 Day Trial

ALL ACCESS PASS

$ 7

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!

MoonLake Immunotherapeutics Price Quote

$46.48
-0.28 (-0.6%)
(Updated: November 4, 2024 at 5:55 PM ET)

MoonLake Immunotherapeutics Key Stats

Sell
39
MoonLake Immunotherapeutics (MLTX) is a Sell
Day range:
$46.04 - $47.23
52-week range:
$35.11 - $64.98
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
5.65%
Volume:
244K
Avg. volume:
364.5K
1-year change:
-3.71%
Market cap:
$2.9B
Revenue:
$0
EPS:
$-0.89

How Much Does MoonLake Immunotherapeutics Make?

Data Unavailable

Is MoonLake Immunotherapeutics Growing As A Company?

Data Unavailable

MoonLake Immunotherapeutics Stock Price Performance

What Is MoonLake Immunotherapeutics 52-Week High & Low?

MoonLake Immunotherapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy MoonLake Immunotherapeutics?

Is MoonLake Immunotherapeutics Cash Flow Positive?

  • What Is MLTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$64.4M
  • What Is MoonLake Immunotherapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $79.4M
  • What Is MoonLake Immunotherapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$174.1M

MoonLake Immunotherapeutics Return On Invested Capital

Data Unavailable

MoonLake Immunotherapeutics Earnings Date & Stock Price

MoonLake Immunotherapeutics Competitors

MoonLake Immunotherapeutics Dividend Yield

MoonLake Immunotherapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -37.71%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 11
Hold Recommendations: 3
Sell Recommendations: 0
Price Target: 75.38
Upside from Last Price: 61.22%

Major Shareholders

  • How many MLTX shares are owned by institutional investors?
    96.8M MLTX shares are owned by institutional investors
  • How many MLTX shares are owned by insiders?
    3.5M MLTX shares are owned by insiders